CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
5.4617
1.3%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0366
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 5.3917
Open 5.2917
1-Year Change 284.57%
Day's Range 5.2917 - 5.5217
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 5.4617 0.1500 2.82% 5.3117 5.5317 5.2217
Dec 19, 2024 5.3917 -0.3700 -6.42% 5.7617 5.8217 5.3917
Dec 18, 2024 5.6817 -0.2300 -3.89% 5.9117 6.0317 5.6117
Dec 17, 2024 5.9817 -0.0500 -0.83% 6.0317 6.1117 5.8417
Dec 16, 2024 6.1317 0.0300 0.49% 6.1017 6.2117 5.9917
Dec 13, 2024 6.1017 -0.1800 -2.87% 6.2817 6.3717 6.0917
Dec 12, 2024 6.3617 -0.0200 -0.31% 6.3817 6.5417 6.3317
Dec 11, 2024 6.4417 -0.2800 -4.17% 6.7217 6.7317 6.4417
Dec 10, 2024 6.6917 0.0900 1.36% 6.6017 6.8117 6.5317
Dec 9, 2024 6.5917 -0.0800 -1.20% 6.6717 6.9717 6.5317
Dec 6, 2024 6.7117 -0.1400 -2.04% 6.8517 7.0117 6.6017
Dec 5, 2024 6.6317 -0.8100 -10.88% 7.4417 7.4417 6.6117
Dec 4, 2024 7.5017 -0.0500 -0.66% 7.5517 7.7617 7.4317
Dec 3, 2024 7.5817 0.1500 2.02% 7.4317 7.6917 7.4017
Dec 2, 2024 7.5517 -0.1900 -2.45% 7.7417 7.8017 7.5317
Nov 29, 2024 7.7117 0.1000 1.31% 7.6117 7.9517 7.6117
Nov 27, 2024 7.6217 0.0500 0.66% 7.5717 7.8717 7.5017
Nov 26, 2024 7.5817 0.3400 4.70% 7.2417 7.7217 7.1417
Nov 25, 2024 7.4217 -0.0100 -0.13% 7.4317 7.5017 7.2517
Nov 22, 2024 7.4217 -0.0300 -0.40% 7.4517 7.5117 7.0817

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Chromadex Corp Company profile

About Chromadex Corp

ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.

Equity composition

Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.

Industry: Biotechnology & Medical Research (NEC)

10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US

People also watch

ETH/USD

3,326.39 Price
+0.300% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

US100

21,269.40 Price
+0.710% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

2.25 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01120

Gold

2,623.59 Price
+1.110% 1D Chg, %
Long position overnight fee -0.0151%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading